jueves, 2 de abril de 2015

Experimental Ebola Vaccine Safe, Prompts Immune Response

Experimental Ebola Vaccine Safe, Prompts Immune Response





Experimental Ebola Vaccine Safe, Prompts Immune ResponseResults from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
An early-stage clinical trial of VSV-ZEBOV, an experimental Ebola vaccine, found that it was safe and prompted robust antibody responses in all 40 of the healthy adults who received it. Preliminary results of the clinical trial, conducted by U.S. government scientists from NIAID and the Walter Reed Army Institute of Research, were published online in The New England Journal of Medicine. The VSV-ZEBOV experimental vaccine is one of two candidate Ebola vaccines now being tested in the phase 2/3 PREVAIL trial that is enrolling volunteers in Liberia.
Read More

No hay comentarios:

Publicar un comentario